may be delivered directly to the eye for example topical ocular drops or ointments slow release devices in the cul de sac or implanted adjacent to the sclera transscleral or within the eye periocular conjunctival sub tenons intracameral intravitreal sub retinal retrobulbar or intracanalicular injections or systemically for example oral intravenous subcutaneous or intramuscular injections parenterally dermal delivery using techniques well known by those skilled in the art it is further contemplated that the antagonists of the invention may be formulated in a placement device such as a retinal pellet intraocular insert catheter suppository or an implant device comprising a porous non porous or gelatinous material intracameral injection may be through the cornea into the anterior chamber to allow the agent to reach the trabecular meshwork intracanalicular injection may be into the venous collector channels draining schlemm 39 s canal or into schlemm 39 s canal subject a subject in need of treatment for an ocular disorder or at risk for developing an ocular disorder is a human or other mammal having a condition or at risk of having a condition associated with inappropriate signaling by ctgf such an ocular disorder may include for example ocular hypertension glaucoma macular degeneration diabetic retinopathy choroidal neovascularization proliferative vitreoretinopathy and conditions with endothelial cell proliferation or fibroproliferation ocular structures associated with such disorders may include the retina choroid lens trabecular meshwork rod cone rpe ganglia macula iris sclera aqueous chamber vitreous chamber ciliary body.